Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here ...

Despite the widespread popularity of new weight-loss medications, research suggests a non-drug alternative is significantly ...

The GLP-1 receptor agonist is approved in India as an adjunct to diet and exercise for adults with type 2 diabetes ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

Ozempic, launched by Novo Nordisk in India at $24.35 weekly, aims to tap into the growing diabetes and obesity market. Despite competition looming with patent expiration next year, the company ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with ...

Novo Nordisk launches Ozempic in India, outlining prices, doses, and its bid to capture rising diabetes and weight-loss ...

With India facing over 101 million cases of diabetes and rising obesity levels, the drug could play a significant role in ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...